The Covid-19 pandemic is almost over. On the one hand, vaccination efforts are underway, while countries are taking steps towards normalization. Vaccination, however, has sparked new controversy over safety.
Currently, there are three vaccines in our country: Sputnik V, Sinovac, and BioNTech. The vaccine at the center of the controversy is Sinovac, which is the most widely used vaccine in our country and comes from China. According to the latest information, the discussions are about to end.
European Medicines Agency begins testing of Chinese vaccine Sinovac
The EMA said in a statement that the decision to begin preliminary evaluation of the “Inactive Covid-19 Vaccine (Vero Cell)” was based on initial results from laboratory and clinical trials. Initial results showed that the vaccine produced antibodies to the virus that causes Covid-19.
The agency will update the information as new details emerge about the Chinese vaccine and will investigate whether the vaccine is sufficient for European Union standards. The review will continue until sufficient evidence is obtained. If Sinovac fails this process, an official application can be made for approval of use in the EU.
EMA officials did not say how long the assessment would take. However, the agency keeps the process much shorter than normal due to the urgency of vaccination efforts.